GlassScriptPhysician profile
Justin Hovey
NPI 1801970116
$66,595.99
in general payments reported to CMS, 2019-2025
42 companies · $30K in 2025
The $30K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,350 · 2020: $8,024 · 2021: $3,133 · 2022: $7,289 · 2023: $11K · 2024: $5,939 · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $34K · Consulting Fee: $6,400 · Food and Beverage: $4,422 · Travel and Lodging: $2,110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $33,867.50 |
| Consulting Fee | $6,400.00 |
| Food and Beverage | $4,422.33 |
| Travel and Lodging | $2,109.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $26,615.58 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $10,726.37 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $7,603.71 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $6,646.50 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Allergan, INC. | $4,533.88 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $2,564.93 | 2020-2021 | |
| Novo Nordisk INC | $1,540.97 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $1,305.42 | 2019-2025 | Spravato, Xarelto |
| Merck Sharp & Dohme LLC | $672.25 | 2020-2025 | Verquvo, Belsomra, Lagevrio |
| Bayer Healthcare Pharmaceuticals INC. | $436.61 | 2022-2025 | |
| Pfizer INC. | $392.81 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $382.48 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $382.23 | 2020-2025 | Rexulti, Abilify Maintena |
| Astrazeneca Pharmaceuticals LP | $359.96 | 2019-2024 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $292.74 | 2019-2024 | Repatha, Otezla, Prolia |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Hovey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.